Home / Leaderboard / Amgen Inc.
Amgen Inc.
Robert A. Bradway · Venture Capital · Venture
Amgen Inc. is a global biotechnology pioneer founded in 1980 and headquartered in Thousand Oaks, California. While primarily known as a leading pharmaceutical company focused on human therapeutics, Amgen operates as a significant corporate investor through its strategic venture capital arm, Amgen Ventures. Established in 2004, Amgen Ventures invests in early-stage biotechnology companies developing innovative medicines and technologies that align with Amgen's core therapeutic areas, such as oncology, inflammation, and cardiovascular disease. The company's investment activities are strategic in nature, aiming to foster external innovation and support the development of breakthrough therapies that may eventually integrate with its own robust research and development pipeline.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +9.0% |
| YTD return | +20.1% |
| Sharpe ratio | -1.00 |
| Win rate | 50% |
| AUM | $0.0B |
| Inception | Oct 1, 2025 |
| Updated | Sep 22, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.0B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.amgen.com |
Current Holdings
Updated on Sep 22, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| ONC | BeiGene, Ltd. | 98.5% | +9.8% |
| NMRA | Neumora Therapeutics, Inc. | 1.5% | -56.3% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Oct 1, 2025 | BUY | ONC | 0.0% → 98.7% |
| Oct 1, 2025 | BUY | NMRA | 0.0% → 1.3% |
Investment Style Analysis
Amgen Inc. is widely recognized for employing a Venture strategy. As of Sep 22, 2026, the firm oversees approximately $0.0B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Oct 1, Amgen Inc. made a significant move by increasing exposure to ONC. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Amgen's investment philosophy is driven by a commitment to advancing human health through scientific innovation. The company's strategy focuses on identifying and supporting early-stage biotechnology firms that are developing transformative treatments for serious illnesses with high unmet medical needs. Amgen prioritizes strategic alignment, seeking investments that complement its expertise in human genetics and biologic medicines. Beyond capital, Amgen provides its portfolio companies with access to its global manufacturing capabilities, regulatory insights, and extensive R&D resources, aiming to accelerate the delivery of life-changing medicines while building a sustainable ecosystem for long-term growth and patient benefit.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Amgen Inc..
Similar Investment Style
Based on Venture.
- Accel Partners — Jim Swartz · 3M +29.0%
- Deer Management Co. LLC — Robert P. Goodman · 3M -6.3%
- New Enterprise Associates, Inc. — Scott Sandell · 3M +1.4%
- Nextech Invest Ltd. — Alfred Scheidegger · 3M +4.6%
Frequently asked questions
How is the simulated portfolio for Amgen Inc. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Amgen Inc.'s largest holding?
As of the latest filing, Amgen Inc.'s top position is BeiGene, Ltd. (ONC), representing 98.5% of the portfolio. This reflects a high-conviction bet by the institution.
What is Amgen Inc.'s historical performance and risk profile?
Our simulation indicates a total return of +9.0% with a win rate of 50%. Notably, the portfolio maintains a Sharpe Ratio of -1.00, suggesting an standard level of risk-adjusted returns compared to the broader market.
What sectors does Amgen Inc. primarily invest in?
Amgen Inc. has a strong preference for the Biotechnology sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Amgen Inc.'s portfolio concentrated or diversified?
Amgen Inc. runs a highly concentrated portfolio with 2 disclosed positions. The top 3 holdings alone account for 100.0% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Amgen Inc. performed in 2026?
Our AI-simulated model portfolio for Amgen Inc. tracks a Year-to-Date (YTD) return of +20.1%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Robert A. Bradway manage Amgen Inc. directly?
Yes, Robert A. Bradway serves as the key portfolio manager for Amgen Inc., overseeing the investment strategy and final capital allocation decisions.